Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma

Authors: Dmitry A. Nosov, Brooke Esteves, Oleg N. Lipatov, Alexei A. Lyulko, A. A. Anischenko, Raju T. Chacko, Dinesh C. Doval, Andrew Strahs, William J. Slichenmyer, Pankaj Bhargava. Click here for link to article.

Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma

Click Here To View Our ASCO Poster:

TIVO-3: Final OS Analysis Of A Phase III, Randomized, Controlled, Multicenter, Open-Label Study To Compare Tivozanib To Sorafenib In Subjects With Metastatic Renal Cell Carcinoma (RCC)